Theresa Pinder
Physician Assistant · Phoenix, AZNPI 1124047246
Payments from drug & device makers
Across 769 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Boehringer Ingelheim$894
- Grifols USA, LLC$838
- plus $8K from 42 others
What the payments were for
- Consulting fees$3992%
- Food & beverage$15,46995%
- Education$3692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$522
- TEZSPIRE$522
- FASENRA$522
- BREZTRI$382
- LUMRYZ$200
- IMFINZI$160
- Inspire Upper Airway Stimulation System$141
- Nalu Neurostimulation System$114
How this compares
$16,237 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 215 | $219,802 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $58,374 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $56,701 |
| Spiriva RespimatTiotropium Bromide | 57 | $52,596 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $21,974 |
| XolairOmalizumab | 13 | $20,896 |
| Qvar RedihalerBeclomethasone Dipropionate | 31 | $12,980 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $12,785 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $12,187 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $11,673 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $11,127 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $9,180 |
| DuleraMometasone/Formoterol | 13 | $7,478 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $7,229 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 153 | $6,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,139 | $306,171352 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $894 | $74,57088 claims |
| CSL BehringHizentra | $415 | $58,37413 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,719 | $23,91247 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $13 | $12,98031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.
Other physician assistant in Phoenix
- Alyssa BoschenPhoenix$86K
- Katherine MinorPhoenix$76K
- Micah LasleyPhoenix$52K
- Thomas SirrinePhoenix$37K
- Karla HortonPhoenix$36K
- Larissa AnthonyPhoenix$32K
- Tana FrumentoPhoenix$25K
- Rosemary SrisukPhoenix$17K
- John DorseyPhoenix$17K
- Kendall SmithPhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.